歌礼制药-B(01672)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01672 歌礼制药-B

未开盘 02-13 16:08:09

16.420

-0.420

-2.49%

最高16.800	最低16.200	成交量138.10万
今开16.800	昨收16.840	日振幅3.56%
总市值174.22亿	流通市值174.22亿	总股本10.61亿
成交额2,270万	换手率0.13%	流通股本10.61亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01672","market":"HK","secType":"STK","nameCN":"歌礼制药-B","latestPrice":16.42,"timestamp":1770970089000,"preClose":16.84,"halted":0,"volume":1381000,"delay":0,"changeRate":-0.02494061757719704,"floatShares":1061000000,"shares":1061000000,"eps":-0.300458,"marketStatus":"未开盘","change":-0.42,"latestTime":"02-13 16:08:09","open":16.8,"high":16.8,"low":16.2,"amount":22696036,"amplitude":0.035629,"askPrice":16.45,"askSize":1000,"bidPrice":16.41,"bidSize":548000,"shortable":3,"etf":0,"ttmEps":-0.267,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1771205400000},"marketStatusCode":0,"adr":0,"listingDate":1533052800000,"exchange":"SEHK","adjPreClose":16.84,"openAndCloseTimeList":[[1770946200000,1770955200000],[1770958800000,1770969600000]],"volumeRatio":0.2116400105463214,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01672/wiki","defaultTab":"wiki","newsList":[{"id":"2611596900","title":"智通特供｜南向1.41万亿“压舱” 韩国散户“点火”——港股迎来定价权分层时代","url":"https://stock-news.laohu8.com/highlight/detail?id=2611596900","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611596900?lang=zh_cn&edition=full","pubTime":"2026-02-13 09:45","pubTimestamp":1770947145,"startTime":"0","endTime":"0","summary":"2025年至2026年初，港股市场迎来两股特征迥异、但方向共振的增量资金——内地南向资金以1.41万亿港元的年度净买入刷新历史纪录，成为港股定价权的核心构建者；韩国散户资金则以“东学蚂蚁”式的集中押注、高杠杆交易及对前沿科技的极致追逐，在港股边缘地带掀起结构性浪潮。截至2025年末，南向资金累计净流入达5.11万亿港元，2025年当年净买入1.41万亿港元，规模接近2022至2024年三年总和。持仓市值突破6.3万亿港元，占港股总市值比重升至12.7%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1404986.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2328871848.SGD","LU0259732245.USD","SG9999015986.USD","SG9999015978.USD","BK1594","LU0054450605.USD","LU2506951792.HKD","LU0229945570.USD","LU2097828805.USD","BK1539","LU0505663152.USD","LU0540923850.HKD","LU0289960550.SGD","LU0348805143.USD","LU0511384066.AUD","LU0819121731.USD","LU0708995583.HKD","LU2778985437.USD","LU0509642566.USD","LU0561508036.HKD","LU1813983027.USD","06160","LU0359201885.HKD","LU0359202008.SGD","LU2153592121.USD","LU0143863198.USD","HYDD.SI","BK1161","81211","BK1610","LU0269904917.USD","LU0449509016.USD","LU0588545730.USD","LU0143863784.USD","VT","01672","BK1500","BYDDY","LU0588545490.SGD","LU2476274308.USD","002594","SG9999015945.SGD","VXUS","LU0543330566.HKD","LU1868837722.USD","LU1720050803.USD","LU0871576103.HKD","LU0165289439.USD"],"gpt_icon":1},{"id":"2611958973","title":"每日卖空追踪 | 歌礼制药-B 02月12日卖空量成交4万股，卖空比例为0.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2611958973","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611958973?lang=zh_cn&edition=full","pubTime":"2026-02-12 16:30","pubTimestamp":1770885024,"startTime":"0","endTime":"0","summary":"歌礼制药-B北京时间02月12日，涨0.42%，卖空量成交4万股，较上一交易日减少91.89%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260212163255a6f28af4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260212163255a6f28af4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1515","01672","BK1161","01477","BK1191"],"gpt_icon":0},{"id":"2611597393","title":"歌礼制药-B02月12日获主力加仓207.8万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2611597393","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611597393?lang=zh_cn&edition=full","pubTime":"2026-02-12 16:15","pubTimestamp":1770884146,"startTime":"0","endTime":"0","summary":"02月12日, 歌礼制药-B股价涨0.42%，报收16.84元，成交金额8669.6万元，换手率0.50%，振幅6.44%，量比0.90。歌礼制药-B今日主力资金净流入207.8万元，上一交易日主力净流入461.1万元。该股近5个交易日上涨21.89%，主力资金累计净流入2654.8万元，其中2个交易日为股价下跌时净流入；近20日主力资金累计净流入3248.6万元，其中净流入天数为13日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260212161957a49b8f05&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260212161957a49b8f05&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","01477","01672","BK1515","BK1161","BK1191"],"gpt_icon":0},{"id":"2610914408","title":"韩国投资者再度扫货中国股票 大举买入大模型龙头MiniMax-WP","url":"https://stock-news.laohu8.com/highlight/detail?id=2610914408","media":"南方财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610914408?lang=zh_cn&edition=full","pubTime":"2026-02-12 14:58","pubTimestamp":1770879513,"startTime":"0","endTime":"0","summary":"南方财经2月12日电，据界面新闻，韩国预托结算院（KSD）旗下SEIbro数据显示，截至2月10日，在港交所市场上，韩国股民年内买入金额排名前十的分别为MiniMax-WP、华夏沪深300ETF、澜起科技、安硕恒生科技ETF、南方东英每日杠杆三星电子、英诺赛科、Premia中国科创50ETF、药明合联、歌礼制药、GlobalX中国半导体ETF。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602123649117334.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["HXC","688366","XPEV","DRAG","07233","CQQQ","BK4588","601881","ASHS","BK4614","03067","000300.SH","CHAU","06826","KWEB","FXI","03188","01672","CWEB","MCHI","HSTECH","BK4585","06881","ASHR","02168","CGXYY","09868","03121"],"gpt_icon":0},{"id":"1111141269","title":"歌礼制药-B：预计2026年第二季度向FDA提交口服减肥药Asc36新药临床试验申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1111141269","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111141269?lang=zh_cn&edition=full","pubTime":"2026-02-11 07:35","pubTimestamp":1770766512,"startTime":"0","endTime":"0","summary":"歌礼制药-B宣布，公司计划于2026年第二季度向美国食品药品监督管理局（FDA）提交其口服片剂Asc36的新药临床试验（IND）申请，该药物拟用于治疗肥胖症。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1574","BK1515","01672"],"gpt_icon":0},{"id":"2610057672","title":"歌礼制药-B(01672)：选定口服胰淀素受体激动剂多肽ASC36进行临床开发","url":"https://stock-news.laohu8.com/highlight/detail?id=2610057672","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610057672?lang=zh_cn&edition=full","pubTime":"2026-02-11 07:06","pubTimestamp":1770764769,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B 发布公告，公司董事会宣布已选定其首款口服胰淀素受体激动剂多肽ASC36口服片进行临床开发。歌礼预计将于2026年第二季度向美国食品药品监督管理局递交ASC36口服片治疗肥胖症的新药临床试验申请。ASC36片亦显著减少了食物摄入。与近期获FDA批准的一款GLP-1R激动剂多肽相比，凭借潜在更优的口服生物利用度和疗效，预计ASC36口服片的给药剂量更低。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1403931.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1191","01672","BK1161","BK1515","01477"],"gpt_icon":0},{"id":"1115224330","title":"歌礼制药（1672）更新翌日披露报表，已发行股本增至约10.61亿股","url":"https://stock-news.laohu8.com/highlight/detail?id=1115224330","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115224330?lang=zh_cn&edition=full","pubTime":"2026-02-10 18:16","pubTimestamp":1770718565,"startTime":"0","endTime":"0","summary":"歌礼制药有限公司于2026年2月10日发布翌日披露报表，披露新股发行及回购股份拟注销等事项。公告显示，公司在2026年2月10日根据一般授权配发及发行69,256,000股新股份，占期初已发行股本约6.98%，每股发行价为12.18港元。发行完成后，公司已发行股本由991,874,320股增至1,061,130,320股，库藏股维持7,084,210股，总股本变动为1,068,214,530股。此外，公司披露2025年4月至12月期间多次回购股份，累计回购5,786,000股，价格区间介乎每股4.8531港元至14.5794港元，上述股份暂未注销。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672"],"gpt_icon":0},{"id":"2610648244","title":"歌礼制药-B(01672)完成配售6925.6万股股份 净筹约8.35亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2610648244","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610648244?lang=zh_cn&edition=full","pubTime":"2026-02-10 17:32","pubTimestamp":1770715961,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B(01672)公布，已于2026年2月10日完成配售合共6925.6万股股份，每股配售价12.18港元，净筹约8.35亿港元，约90%建议用于治疗肥胖症的小分子口服GLP-1受体激动剂ASC30的全球III期临床试验的准备、基础工作及启动，约10%建议用作营运资金及其他一般公司用途。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1403717.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01477","01672","BK1515","BK1191","BK1161","BK1574"],"gpt_icon":0},{"id":"2610003646","title":"每日卖空追踪 | 歌礼制药-B 02月10日卖空量成交20.9万股，卖空比例为4.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2610003646","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610003646?lang=zh_cn&edition=full","pubTime":"2026-02-10 16:30","pubTimestamp":1770712225,"startTime":"0","endTime":"0","summary":"歌礼制药-B北京时间02月10日，涨5.15%，卖空量成交20.9万股，较上一交易日减少7.93%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260210163313a492b9a7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260210163313a492b9a7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","BK1191","BK1574","01672","BK1161","01477"],"gpt_icon":0},{"id":"2610649887","title":"歌礼制药-B02月10日获主力加仓1393.0万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2610649887","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610649887?lang=zh_cn&edition=full","pubTime":"2026-02-10 16:15","pubTimestamp":1770711339,"startTime":"0","endTime":"0","summary":"02月10日, 歌礼制药-B股价涨5.15%，报收17.14元，成交金额8694.2万元，换手率0.51%，振幅6.75%，量比1.15。歌礼制药-B今日主力资金净流入1393.0万元，连续7日净流入，上一交易日主力净流入51.3万元。该股近5个交易日上涨31.57%，主力资金累计净流入2449.9万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入2943.0万元，其中净流入天数为12日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260210161831a6e99934&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260210161831a6e99934&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","01477","BK1574","BK1191","BK1515","01672"],"gpt_icon":0},{"id":"2610884649","title":"歌礼制药-B再涨超6% ASC30加速全球III期临床 机构称BD潜力较大","url":"https://stock-news.laohu8.com/highlight/detail?id=2610884649","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610884649?lang=zh_cn&edition=full","pubTime":"2026-02-10 14:52","pubTimestamp":1770706348,"startTime":"0","endTime":"0","summary":"歌礼制药-B再涨超6%，截至发稿，涨5.52%，报17.2港元，成交额6945.8万港元。消息面上，GIC在歌礼制药最新一轮配售中获得头部分配额度，将助力ASC30加速全球III期临床推进。交易完成后，GIC持有歌礼制药6.42%股权。东方证券表示，ASC30减重数据优越，安全性良好，且分子专利已获美国授权，BD潜力较大。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260210150504a49257bd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260210150504a49257bd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1515","BK1161","BK1191","01477","01672"],"gpt_icon":0},{"id":"1116933064","title":"港股异动 | 歌礼制药盘中涨超8%，GIC斥资7.81亿港元增持歌礼制药，持股比例已达6.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=1116933064","media":"老虎资讯综合","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1116933064?lang=zh_cn&edition=full","pubTime":"2026-02-09 10:01","pubTimestamp":1770602515,"startTime":"0","endTime":"0","summary":"2月9日，$歌礼制药-B$盘中涨超8%，GIC斥资7.81亿港元增持歌礼制药，持股比例已达6.42%。消息面上，2月6日，$港交所$披露的信息显示，新加坡政府投资基金以每股均价12.18港元的价格，斥资约7.81亿港元买入歌礼制药6412.8万股新股。交易完成后，GIC持有歌礼制药6.42%股权。公开资料显示，此次入股源于歌礼制药近期完成对配股计划。GIC在此轮配售中获得头部分配额度。","market":"hk","thumbnail":"https://static.tigerbbs.com/df4ec61541b268a5353585001973d7cb","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/df4ec61541b268a5353585001973d7cb"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"8173ebb445828bbdab4a68b6f572d4e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672","BK1574","BK4585","BK1161","BK1515","BK4104","BK4588","BK1191","01477"],"gpt_icon":0},{"id":"2610501497","title":"港股异动 | 歌礼制药-B(01672)早盘涨近9% GIC斥资7.81亿港元增持歌礼制药 持股比例已达6.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=2610501497","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610501497?lang=zh_cn&edition=full","pubTime":"2026-02-09 09:43","pubTimestamp":1770601432,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，歌礼制药-B早盘涨近9%，截至发稿，涨8.29%，报16.46港元，成交额1428.9万港元。消息面上，2月6日，港交所披露的信息显示，新加坡政府投资基金以每股均价12.18港元的价格，斥资约7.81亿港元买入歌礼制药6412.8万股新股。交易完成后，GIC持有歌礼制药6.42%股权。公开资料显示，此次入股源于歌礼制药近期完成对配股计划。GIC在此轮配售中获得头部分配额度。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"8173ebb445828bbdab4a68b6f572d4e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1402978.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","GIC","BK4104","BK4588","VT","01672","BK4585","01477","VXUS","BK1161","BK1574","BK1515"],"gpt_icon":0},{"id":"2609596974","title":"歌礼制药-B(01672.HK)获GIC Private Limited增持6412.8万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2609596974","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609596974?lang=zh_cn&edition=full","pubTime":"2026-02-06 21:17","pubTimestamp":1770383821,"startTime":"0","endTime":"0","summary":"格隆汇2月6日丨根据联交所最新权益披露资料显示，2026年2月3日，歌礼制药-B(01672.HK)获GIC Private Limited在场内以每股均价12.18港元增持6412.8万股，涉资约7.81亿港元。\r\n\r\n　　增持后，GIC Private Limited最新持股数目为6412.8万股，持股比例为6.42%。","market":"fut","thumbnail":" http://caiji.3g.cnfol.com/colect/202602/06/20260206499677.jpg","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202602/06/20260206499677.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260206/32004708.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["GIC","BK1161","BK4104","01477","BK1574","BK1515","01672","BK1191"],"gpt_icon":0},{"id":"2609273347","title":"东方证券：替尔泊肽加冕新“药王” 未来减重药物商业价值将快速释放","url":"https://stock-news.laohu8.com/highlight/detail?id=2609273347","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609273347?lang=zh_cn&edition=full","pubTime":"2026-02-05 13:38","pubTimestamp":1770269908,"startTime":"0","endTime":"0","summary":"当前，MNC已将减重视为核心的战略要地，大额BD和并购频现，今年催化密集。东方证券主要观点如下：替尔泊肽加冕“药王”，减重药物将霸榜2026年2月4日，礼来发布2025年业绩，替尔泊肽全年销售365.07亿美元，加冕2025年全球“药王”，并有望多年蝉联。据Evaluate预测，到2030年全球销售额前十药物中约半数为GLP-1类药物。减重BD未停，新方向需求将起去年末以来，减重领域交易仍在持续。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1401960.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2039709279.SGD","LU1226287792.SGD","LU1226288253.USD","IE00B543WZ88.USD","LU1152091754.HKD","LU0140636845.USD","IE0008368742.USD","LU1226287875.USD","IE00B5MMRT66.SGD","IE00BZ08YS42.EUR","BK1147","LU1951186391.HKD","LU1152091168.USD","IE00B031HY20.USD","BK1521","BK1574","LU1328277881.USD","IE00BZ08YR35.GBP","LU1226287529.USD","01672","600958","BK1191","LU0067412154.USD","LU1008478684.HKD","SG9999004220.SGD","LU0072913022.USD","BK1515","03958","BK0188","LU1807302812.USD","BK1564","LU1993786604.SGD","LU1226288170.HKD","LU0315179316.USD","LU0326950275.SGD","LU0501845795.SGD","BK1161","LU0314109678.HKD","LU0880133367.SGD","IE0008369823.USD","BK0276","LU1960683339.HKD","BK0183","LU1813983027.USD","01093","BK0028","BK0012","IE00BZ08YT58.USD","HK0000165453.HKD"],"gpt_icon":0},{"id":"2609301751","title":"歌礼制药-B盘中异动 股价大跌5.30%","url":"https://stock-news.laohu8.com/highlight/detail?id=2609301751","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609301751?lang=zh_cn&edition=full","pubTime":"2026-02-05 10:59","pubTimestamp":1770260396,"startTime":"0","endTime":"0","summary":"2026年02月05日早盘10时59分，歌礼制药-B股票出现波动，股价大幅下跌5.30%。截至发稿，该股报13.220港元/股，成交量84.7万股，换手率0.09%，振幅7.02%。机构评级方面，在所有1家参与评级的机构中，100%的券商给予持有建议，无券商给予买入、卖出建议。歌礼制药-B股票所在的生物技术行业中，整体跌幅为0.71%。其相关个股中，银诺医药-B、药捷安康-B、中生北控生物科技涨幅较大，振幅较大的相关个股有银诺医药-B、北海康成-B、MIRXES-B，振幅分别为20.06%、16.50%、10.94%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260205105957a6d52827&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260205105957a6d52827&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","01477","BK1191","BK1574","01672","BK1161"],"gpt_icon":0},{"id":"1166254163","title":"歌礼制药（01672）2026年1月股份变动月报表，股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1166254163","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166254163?lang=zh_cn&edition=full","pubTime":"2026-02-03 19:01","pubTimestamp":1770116464,"startTime":"0","endTime":"0","summary":"歌礼制药有限公司于2026年2月3日披露2026年1月股份变动月报表，报告期截至2026年1月31日。公告显示，公司注册股本维持在7,000,000,000股，每股面值USD 0.0001，总注册资本USD 700,000。截至本月末，已发行股份总数为991,874,320股，库存股份数为7,084,210股，两者合计998,958,530股，均与上月保持一致。同时，此前于2025年回购的多批普通股仍处于拟注销状态，截至2026年1月31日尚未注销，未对本期股份数量构成影响。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672"],"gpt_icon":0},{"id":"2608876023","title":"每日卖空追踪 | 歌礼制药-B 02月03日卖空量成交46.8万股，卖空比例为13.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608876023","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608876023?lang=zh_cn&edition=full","pubTime":"2026-02-03 16:30","pubTimestamp":1770107423,"startTime":"0","endTime":"0","summary":"歌礼制药-B北京时间02月03日，涨3.07%，卖空量成交46.8万股，较上一交易日减少57.3%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260203163357a6cdb6f5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260203163357a6cdb6f5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","01477","BK1574","BK1515","01672","BK1191"],"gpt_icon":0},{"id":"2608845081","title":"歌礼制药配售价较前收盘每股12.69港元折让4.0%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2608845081","media":"新浪财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608845081?lang=zh_cn&edition=full","pubTime":"2026-02-03 07:44","pubTimestamp":1770075895,"startTime":"0","endTime":"0","summary":"来源：滚动播报歌礼制药配售价较前收盘每股12.69港元折让4.0%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260203074752a474e148&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260203074752a474e148&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01672","01477","BK1191","BK1515","BK1574","BK1161"],"gpt_icon":0},{"id":"2608816051","title":"歌礼制药-B(01672)拟折让约4%配售6925.6万股 净筹约8.353亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608816051","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608816051?lang=zh_cn&edition=full","pubTime":"2026-02-03 07:38","pubTimestamp":1770075525,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B(01672)发布公告，于2026年2月3日，公司拟配售6925.6万股，占公司于本公告日期已发行股份数目(即9.92亿股股份，不包括708.42万股库存股份)约6.98%。每股配售股份的配售价12.18港元，较2月2日收市价每股股份12.69港元折让约4.0%。配售所得款项总额预期合共约为8.435亿港元，而配售所得款项净额预期合共约为8.353亿港元。配售事项所得款项净额中约90%建议用于治疗肥胖症的小分子口服GLP-1受体激动剂ASC30的全球III期临床试验的准备、基础工作及启动，而配售事项所得款项净额中约10%建议用作营运资金及其他一般公司用途。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1400799.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","01672","01477","BK1161","BK1574","BK1515"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ascletis.com","stockEarnings":[{"period":"1week","weight":0.0803},{"period":"1month","weight":0.2127},{"period":"3month","weight":0.1951},{"period":"6month","weight":-0.0744},{"period":"1year","weight":3.0744},{"period":"ytd","weight":0.4416}],"compareEarnings":[{"period":"1week","weight":0.0003},{"period":"1month","weight":-0.016},{"period":"3month","weight":-0.0187},{"period":"6month","weight":0.0513},{"period":"1year","weight":0.2179},{"period":"ytd","weight":0.0365}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"歌礼制药有限公司是一家主要从事医药产品研发、生产和销售的投资控股公司。该公司专注于病毒性疾病、非酒精性脂肪性肝炎（NASH）或原发性胆汁性胆管炎（PBC）及肿瘤领域。该公司的产品管线包括用于慢性乙肝功能性治愈的ASC22、用于呼吸道合胞病毒（RSV）的ASC10、用于人类免疫缺陷病毒（HIV）功能性治愈的ASC22、用於新冠肺炎的ASC10及ASC11、用於NASH的ASC41、用於PBC的ASC42、用于实体瘤的ASC61、用于中、重度痤疮的ASC40等。该公司在国内和国外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.75,"avgChangeRate":0.146882},{"month":2,"riseRate":0.75,"avgChangeRate":0.106037},{"month":3,"riseRate":0.285714,"avgChangeRate":-0.058802},{"month":4,"riseRate":0.428571,"avgChangeRate":-0.059274},{"month":5,"riseRate":0.428571,"avgChangeRate":0.007612},{"month":6,"riseRate":0.428571,"avgChangeRate":-0.024499},{"month":7,"riseRate":0.571429,"avgChangeRate":0.032162},{"month":8,"riseRate":0.285714,"avgChangeRate":-0.037953},{"month":9,"riseRate":0.125,"avgChangeRate":-0.072967},{"month":10,"riseRate":0.5,"avgChangeRate":-0.023171},{"month":11,"riseRate":0.875,"avgChangeRate":0.185422},{"month":12,"riseRate":0.5,"avgChangeRate":0.087327}],"exchange":"SEHK","name":"歌礼制药-B","nameEN":"ASCLETIS-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"歌礼制药-B(01672)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供歌礼制药-B(01672)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"歌礼制药-B,01672,歌礼制药-B股票,歌礼制药-B股票老虎,歌礼制药-B股票老虎国际,歌礼制药-B行情,歌礼制药-B股票行情,歌礼制药-B股价,歌礼制药-B股市,歌礼制药-B股票价格,歌礼制药-B股票交易,歌礼制药-B股票购买,歌礼制药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"歌礼制药-B(01672)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供歌礼制药-B(01672)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}